凭借司美格鲁肽系列降糖、减重药物走红的医药巨头诺和诺德,正陷入多重经营困境。 近期,数十名美国患者集体起诉诺和诺德,指控该公司旗下司美格鲁肽类药物引发严重视力损伤,相关案件已进入美国联邦法院集中审理。 在美国的诉讼爆发之前,丹麦也出现了88起类似的理赔申请案例。目前,欧洲监管机构已经将非动脉炎性前部缺血性视神经病变(NAION)列为司美格鲁肽药物的“非常罕见”副作用。 与此同时,诺和诺德还...
Source Link凭借司美格鲁肽系列降糖、减重药物走红的医药巨头诺和诺德,正陷入多重经营困境。 近期,数十名美国患者集体起诉诺和诺德,指控该公司旗下司美格鲁肽类药物引发严重视力损伤,相关案件已进入美国联邦法院集中审理。 在美国的诉讼爆发之前,丹麦也出现了88起类似的理赔申请案例。目前,欧洲监管机构已经将非动脉炎性前部缺血性视神经病变(NAION)列为司美格鲁肽药物的“非常罕见”副作用。 与此同时,诺和诺德还...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.